Literature DB >> 21615795

Acute chest syndrome: sickle cell disease.

Rabindra N Paul1, Oswaldo L Castro, Anita Aggarwal, Patricia A Oneal.   

Abstract

Acute chest syndrome (ACS) is a common complication and reason for hospital admission in patients with sickle cell disease (SCD). It is also the most common cause of death in this patient population. Most of the time, the trigger for ACS in an individual patient cannot be identified. However, although infection is the most common identifiable cause for ACS, other important triggers are vaso-occlusive crisis (VOC) and asthma. This comprehensive review will focus on the pathogenesis, clinical characteristics, complications and treatment available to manage ACS. But importantly, this review will highlight new possible etiologies, with the goal of improving oxygenation and, therefore, a reduction in sickling and lung damage in this patient population.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615795     DOI: 10.1111/j.1600-0609.2011.01647.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  19 in total

1.  Repurposing pyridoxamine for therapeutic intervention of intravascular cell-cell interactions in mouse models of sickle cell disease.

Authors:  Jing Li; Si-Yeon Jeong; Bei Xiong; Alan Tseng; Andrew B Mahon; Steven Isaacman; Victor R Gordeuk; Jaehyung Cho
Journal:  Haematologica       Date:  2019-10-31       Impact factor: 9.941

Review 2.  Improving outcomes in children with sickle cell disease: treatment considerations and strategies.

Authors:  Ali Amid; Isaac Odame
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

Review 3.  Novel insights in the management of sickle cell disease in childhood.

Authors:  Lorenzo Iughetti; Elena Bigi; Donatella Venturelli
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 4.  Sickle cell disease in children.

Authors:  Emily Riehm Meier; Jeffery L Miller
Journal:  Drugs       Date:  2012-05-07       Impact factor: 9.546

Review 5.  Molecular mechanisms of hepatic dysfunction in sickle cell disease: lessons from Townes mouse model.

Authors:  Tirthadipa Pradhan-Sundd; Gregory J Kato; Enrico M Novelli
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-27       Impact factor: 5.282

6.  A cortactin CTTN coding SNP contributes to lung vascular permeability and inflammatory disease severity in African descent subjects.

Authors:  Patrick Belvitch; Nancy Casanova; Xiaoguang Sun; Sara M Camp; Saad Sammani; Mary E Brown; Joseph Mascarhenas; Heather Lynn; Djanybek Adyshev; Jessica Siegler; Ankit Desai; Laleh Seyed-Saadat; Alicia Rizzo; Christian Bime; Gajendra S Shekhawat; Vinayak P Dravid; John P Reilly; Tiffanie K Jones; Rui Feng; Eleftheria Letsiou; Nuala J Meyer; Nathan Ellis; Joe G N Garcia; Steven M Dudek
Journal:  Transl Res       Date:  2022-02-15       Impact factor: 10.171

7.  Splenic morphological changes are accompanied by altered baseline immunity in a mouse model of sickle-cell disease.

Authors:  Steven M Szczepanek; Jeffrey T McNamara; Eric R Secor; Prabitha Natarajan; Linda A Guernsey; Lauren A Miller; Enrique Ballesteros; Evan Jellison; Roger S Thrall; Biree Andemariam
Journal:  Am J Pathol       Date:  2012-09-19       Impact factor: 4.307

Review 8.  Minireview: Genetic basis of heterogeneity and severity in sickle cell disease.

Authors:  Alawi Habara; Martin H Steinberg
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-01

Review 9.  Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).

Authors:  Ademola Samson Adewoyin
Journal:  Anemia       Date:  2015-01-18

10.  Nocturnal hypoxemia measured by polysomnogram is associated with acute chest syndrome in pediatric sickle cell disease.

Authors:  Anis Rabbani Nourani; A K M Fazlur Rahman; Brandi Pernell; Mary H Maddox; Lee Hilliard; Jeffrey Lebensburger; Ammar Saadoon Alishlash
Journal:  J Clin Sleep Med       Date:  2021-02-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.